ATRECA INC - A (BCEL) Stock Price, Quote, News and Overview
NASDAQ:BCEL - Nasdaq - US04965G1094 - Common Stock - Currency: USD
BCEL Quote, Performance and Key Statistics
0.15
-0.02 (-11.76%)
The current stock price of BCEL is 0.15 USD. In the past month the price decreased by -51.61%. In the past year, price decreased by -87.8%.
BCEL Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About BCEL
Company Profile
Atreca, Inc. operates as a clinical-stage biopharmaceutical company, which engages in developing novel antibody-based therapeutics to treat a range of solid tumor types. The company is headquartered in San Carlos, California and currently employs 90 full-time employees. The company went IPO on 2019-06-20. The firm is discovering and developing antibody-based therapeutics to treat a range of solid tumor types. Its most advanced product candidate, ATRC-101, is a monoclonal antibody with a mechanism of action and target derived from an antibody identified using its discovery platform. ATRC-101 reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal and breast cancer samples from multiple patients. The company commenced clinical development of ATRC-101 with a Phase Ib clinical trial evaluating ATRC-101 as a monotherapy in patients with select solid tumors and opens a new cohort to evaluate ATRC-101 in combination with pembrolizumab, a PD-1 checkpoint inhibitor. The company is also advancing additional product candidates using its discovery platform. Its oncology programs include APN-497444, an ADC against a tumor glycan target, and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target.
Company Info
ATRECA INC - A
835 Industrial Road,, 75 Shoreway Road, Suite C
San Carlos CALIFORNIA 94063 US
CEO: John A. Orwin
Employees: 90
Company Website: https://www.atreca.com/
Phone: 16505952595
ATRECA INC - A / BCEL FAQ
What is the stock price of ATRECA INC - A today?
The current stock price of BCEL is 0.15 USD. The price decreased by -11.76% in the last trading session.
What is the ticker symbol for ATRECA INC - A stock?
The exchange symbol of ATRECA INC - A is BCEL and it is listed on the Nasdaq exchange.
On which exchange is BCEL stock listed?
BCEL stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ATRECA INC - A stock?
10 analysts have analysed BCEL and the average price target is 5.61 USD. This implies a price increase of 3640% is expected in the next year compared to the current price of 0.15. Check the ATRECA INC - A stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ATRECA INC - A worth?
ATRECA INC - A (BCEL) has a market capitalization of 5.94M USD. This makes BCEL a Nano Cap stock.
How many employees does ATRECA INC - A have?
ATRECA INC - A (BCEL) currently has 90 employees.
What are the support and resistance levels for ATRECA INC - A (BCEL) stock?
ATRECA INC - A (BCEL) has a resistance level at 0.36. Check the full technical report for a detailed analysis of BCEL support and resistance levels.
Should I buy ATRECA INC - A (BCEL) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of BCEL, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of BCEL, evaluating the profitability, health, valuation and growth aspects
- ATRECA INC - A (BCEL) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ATRECA INC - A (BCEL) Sales and EPS estimates to see what analysts future expectations are.
- ATRECA INC - A (BCEL) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ATRECA INC - A (BCEL) Insider and Institutional Ownership to learn about the owners and their transactions.
- ATRECA INC - A (BCEL) Stock Chart to make your own analysis
- ATRECA INC - A (BCEL) Latest news and press-releases to stay up to date.
Does ATRECA INC - A (BCEL) stock pay dividends?
BCEL does not pay a dividend.
When does ATRECA INC - A (BCEL) report earnings?
ATRECA INC - A (BCEL) will report earnings on 2024-05-08, after the market close.
What is the Price/Earnings (PE) ratio of ATRECA INC - A (BCEL)?
ATRECA INC - A (BCEL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.95).
BCEL Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to BCEL. When comparing the yearly performance of all stocks, BCEL is a bad performer in the overall market: 97.03% of all stocks are doing better.
BCEL Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to BCEL. While BCEL seems to be doing ok healthwise, there are quite some concerns on its profitability.
BCEL Financial Highlights
Over the last trailing twelve months BCEL reported a non-GAAP Earnings per Share(EPS) of -1.95. The EPS increased by 29.35% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -371.75% | ||
| ROE | -905.28% | ||
| Debt/Equity | 0 |
BCEL Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to BCEL. The Buy consensus is the average rating of analysts ratings from 10 analysts.